The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase I (Group A and Group B): Dose-limiting toxicities (DLTs)
Timeframe: Up to 28 days
Phase I (Group A and Group B): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From date of randomization till 30 days safety fup, assessed up to approximately 79 months
Phase I (Group A and Group B): Number of Participants with dose adjustments
Timeframe: From date of randomization till 30 days safety fup, assessed up to approximately 79 months
Phase I (Group A and Group B): Dose Intensity
Timeframe: From date of randomization till 30 days safety fup, assessed up to approximately 79 months
Phase I (Group A and Group B): Duration of exposure to each study drug
Timeframe: From date of randomization till 30 days safety fup, assessed up to approximately 79 months
Phase II (Group A): Biochemical Response Rate (BCR)
Timeframe: From date of randomization till 30 days safety fup, assessed up to approximately 79 months